Pasar al contenido principal

Simon Schwartz Navarro

Senior scientist and advisor with specific interest in Nanomedicine and Advanced Therapies applied to unmet clinical needs. I am also acting as strategy coordinator to facilitate programs and initiatives that foster innovation in new treatments and diagnostic tools.

Instituciones de las que forman parte

Investigador/a principal
Bioquímica Clínica, Vehiculización de Fármacos y Terapia
Vall Hebron Institut de Recerca
Cap de Secció
Bioquímica
Serveis transversals

Simon Schwartz Navarro

Instituciones de las que forman parte

Investigador/a principal
Bioquímica Clínica, Vehiculización de Fármacos y Terapia
Vall Hebron Institut de Recerca
Cap de Secció
Bioquímica
Serveis transversals

Senior scientist and advisor with specific interest in Nanomedicine and Advanced Therapies applied to unmet clinical needs. I am also acting as strategy coordinator to facilitate programs and initiatives that foster innovation in new treatments and diagnostic tools.

Currently acting as Strategy director of biobanking and bioresources at Vall d'hebron Campus. President of the European Society of Nanomedicine and Executive Board member of the International Society of Nanomedicine. Former director general of the Blood and Tissue Banc of Catalonia. Former director of CIBBIM-Nanomedicine. Former scientific associate director of CIBER-BBN and coordinator of technology transfer. Former director assistance of translational research at VHIR. H-index of 40, with more that 115 high impact publications and 17 transferred patents. Co-founder of 3 biotech companies (i.e, Bsure Medical ltd). Science Advisor of the European Nanomedicine Characterization Laboratory (EU-NCL). Member of the editorial Board of Precision Nanomedicine, J. Nanotechnology and of J. of Nanotheranostics. Former editorial Board member of Eur. J. Nanomedicine and Nanomedicine-NBM.

Proyectos

CIBBIM- Nanomedicine. Drug Delivery and Targeting

IP: Simon Schwartz Navarro
Colaboradores: -
Entidad financiadora: Agència Gestió Ajuts Universitaris i de Recerca
Financiación: 0.01
Referencia: 2017SGR00638
Duración: 01/01/2017 - 31/12/2020

Desenvolupament d¿assaigs preclínics de nanosistemes per estudis clínics amb aplicació en càncer ductal pancreàtic.

IP: Simon Schwartz Navarro
Colaboradores: Miriam Izquierdo Sans
Entidad financiadora: Generalitat de Catalunya - Departament de Salut
Financiación: 67280.97
Referencia: SLT006/17/00270
Duración: 01/03/2018 - 14/05/2021

Terapia combinada mediante nuevos nanoconjugados terapéuticos contra Células Madre Tumorales en tumores de mamas triple negativos

IP: Simon Schwartz Navarro
Colaboradores: Laura García Latorre, Joaquin Seras Franzoso, Fernanda Raquel Da Silva Andrade, Diana Fernandes de Rafael
Entidad financiadora: Instituto de Salud Carlos III
Financiación: 123420
Referencia: PI17/02242
Duración: 01/01/2018 - 31/12/2020

Smart-4-Fabry: Smart multifunctional GLA-nanoformulation for Fabry disease

IP: -
Colaboradores: Smart-4-Fabry: Smart multifunctional GLA-nanoformulation for Fabry disease, Simon Schwartz Navarro, Sandra Mancilla Zamora, Zamira Vanessa Diaz Riascos, Smart-4-Fabry: Smart multifunctional GLA-nanoformulation for Fabry disease, Smart-4-Fabry: Smart multifunctional GLA-nanoformulation for Fabry disease, Smart-4-Fabry: Smart multifunctional GLA-nanoformulation for Fabry disease, Smart-4-Fabry: Smart multifunctional GLA-nanoformulation for Fabry disease, Smart-4-Fabry: Smart multifunctional GLA-nanoformulation for Fabry disease, Smart-4-Fabry: Smart multifunctional GLA-nanoformulation for Fabry disease, Smart-4-Fabry: Smart multifunctional GLA-nanoformulation for Fabry disease, Smart-4-Fabry: Smart multifunctional GLA-nanoformulation for Fabry disease, Smart-4-Fabry: Smart multifunctional GLA-nanoformulation for Fabry disease, Smart-4-Fabry: Smart multifunctional GLA-nanoformulation for Fabry disease, Smart-4-Fabry: Smart multifunctional GLA-nanoformulation for Fabry disease, Smart-4-Fabry: Smart multifunctional GLA-nanoformulation for Fabry disease, Smart-4-Fabry: Smart multifunctional GLA-nanoformulation for Fabry disease, Smart-4-Fabry: Smart multifunctional GLA-nanoformulation for Fabry disease, Smart-4-Fabry: Smart multifunctional GLA-nanoformulation for Fabry disease, Smart-4-Fabry: Smart multifunctional GLA-nanoformulation for Fabry disease, Smart-4-Fabry: Smart multifunctional GLA-nanoformulation for Fabry disease, Smart-4-Fabry: Smart multifunctional GLA-nanoformulation for Fabry disease, Smart-4-Fabry: Smart multifunctional GLA-nanoformulation for Fabry disease, Smart-4-Fabry: Smart multifunctional GLA-nanoformulation for Fabry disease, Smart-4-Fabry: Smart multifunctional GLA-nanoformulation for Fabry disease, Smart-4-Fabry: Smart multifunctional GLA-nanoformulation for Fabry disease, Smart-4-Fabry: Smart multifunctional GLA-nanoformulation for Fabry disease, Smart-4-Fabry: Smart multifunctional GLA-nanoformulation for Fabry disease, Smart-4-Fabry: Smart multifunctional GLA-nanoformulation for Fabry disease, Smart-4-Fabry: Smart multifunctional GLA-nanoformulation for Fabry disease, Smart-4-Fabry: Smart multifunctional GLA-nanoformulation for Fabry disease, Smart-4-Fabry: Smart multifunctional GLA-nanoformulation for Fabry disease, Smart-4-Fabry: Smart multifunctional GLA-nanoformulation for Fabry disease, Smart-4-Fabry: Smart multifunctional GLA-nanoformulation for Fabry disease, Smart-4-Fabry: Smart multifunctional GLA-nanoformulation for Fabry disease, Smart-4-Fabry: Smart multifunctional GLA-nanoformulation for Fabry disease, Smart-4-Fabry: Smart multifunctional GLA-nanoformulation for Fabry disease, Smart-4-Fabry: Smart multifunctional GLA-nanoformulation for Fabry disease, Smart-4-Fabry: Smart multifunctional GLA-nanoformulation for Fabry disease, Smart-4-Fabry: Smart multifunctional GLA-nanoformulation for Fabry disease, Smart-4-Fabry: Smart multifunctional GLA-nanoformulation for Fabry disease, Smart-4-Fabry: Smart multifunctional GLA-nanoformulation for Fabry disease, Smart-4-Fabry: Smart multifunctional GLA-nanoformulation for Fabry disease, Smart-4-Fabry: Smart multifunctional GLA-nanoformulation for Fabry disease
Entidad financiadora: EUROPEAN COMMISSION
Financiación: 266300.8
Referencia: SMART4FABRY_H2020NMBP2016
Duración: 01/01/2017 - 31/12/2020

Noticias relacionadas

Mediante tomografía computerizada (TAC), con o sin contraste, es posible realizar una detección precisa y segura de la enfermedad sin necesidad de biopsias y evitando las limitaciones de otras herramientas diagnósticas no invasivas.

El proyecto europeo, en el que participa Vall d’Hebron, favorecerá el diagnóstico personalizado y estrategias terapéuticas innovadoras en pacientes con la enfermedad.

En total se impulsarán diferentes proyectos de seis grupos de investigación que se centrarán en la medicina de precisión y las terapias avanzadas.

Profesionales relacionados

Monica Bolufer Cardona

Monica Bolufer Cardona

Investigador predoctoral
Nefrología y Trasplante Renal
Leer más
Macarena González Rodríguez

Macarena González Rodríguez

Leer más
Milagros Fraga Pereira

Milagros Fraga Pereira

Auxiliar de investigación
Neuroinmunología Clínica
Leer más
Alvaro Jesus Valverde Moya

Alvaro Jesus Valverde Moya

Investigador predoctoral
Imagen Médica Molecular
Leer más

Suscríbete a nuestros boletines y forma parte de la vida del Campus

Vall d'Hebron Barcelona Hospital Campus es un parque de referencia mundial donde la asistencia, la investigación, la docencia y la innovación se dan la mano.